ClariVest Asset Management’s Editas Medicine EDIT Stock Holding History

ClariVest Asset Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-28,417	Closed	-$348K	–	703
2022 Q3	$348K	Sell	28,417 -78	-0.3%	-$1.22K	0.02%	398
2022 Q2	$337K	Buy	28,495 +9,998	+54%	+$134K	0.01%	420
2022 Q1	$352K	Hold	18,497	–	–	0.01%	428
2021 Q4	$491K	Buy	18,497 +7,615	+70%	+$262K	0.02%	435
2021 Q3	$447K	Buy	+10,882	New	+$596K	0.01%	446

Other funds holding EDIT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ClariVest Asset Management's EDIT Position: Q4 2022 in Review

ClariVest Asset Management sold out of Editas Medicine (EDIT) in Q4 2022, closing a stake of 28,417 shares — an estimated $348K sold.

ClariVest Asset Management first reported a position in EDIT in Q3 2021 and held it in 5 quarters. The position peaked at $491K in Q4 2021. 250 funds tracked by Wall St. Rank hold EDIT as of Q4 2022.

ClariVest Asset Management reported no remaining Editas Medicine position as of Q4 2022 after selling out during the quarter.
ClariVest Asset Management sold 28,417 Editas Medicine shares in Q4 2022, an estimated $348K.
ClariVest Asset Management first reported a position in Editas Medicine in Q3 2021 and held it in 5 quarters.
ClariVest Asset Management's Editas Medicine position peaked at $491K in Q4 2021.
250 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2022.

Based on ClariVest Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.